Bear, you are correct, as always... I misread the population at the top of Cabel's question , and was referring to phase II date with my corrections :\  My apologies Cabel!

Throughout the total BETonMace (Phase III study) population; results are so far not in the direction expected, however, I agree with Bear it is clinically meaningless... most people in this study started with a normal eGFR and ended with a normal eGFR.

And we do not yet have the data  to confirm phase II study results  for the "sick kidney" population, but hoping:

      - that  eGFR <60  patients will have eGFR go up significantly in the treated group and down/at least not up,  in the placebo group... to show APABETALONE both decreases MACE (already proven ) and increases eGFR in sick patients...  with statistical significance. 

That's a good drug even before MoCA improvement, but here's hoping for all !